heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
=== Pre-RNA world: The ribose issue and its bypass === A different type of nucleic acid, such as peptide nucleic acid, threose nucleic acid or glycol nucleic acid, could have been the first to emerge as a self-reproducing molecule, later replaced by RNA. Larralde et al., say that "the generally accepted prebiotic synthesis of ribose, the formose reaction, yields numerous sugars without any selectivity". They conclude that "the backbone of the first genetic material could not have contained ribose or other sugars because of their instability", meaning that the ester linkage of ribose and phosphoric acid in RNA is prone to hydrolysis. Pyrimidine ribonucleosides and nucleotides have been synthesized by reactions which by-pass the free sugars, and are assembled stepwise using nitrogenous or oxygenous chemistries. Sutherland has demonstrated high-yielding routes to cytidine and uridine ribonucleotides from small 2 and 3 carbon fragments such as glycolaldehyde, glyceraldehyde or glyceraldehyde-3-phosphate, cyanamide and cyanoacetylene. A step in this sequence allows the isolation of enantiopure ribose aminooxazoline if the enantiomeric excess of glyceraldehyde is 60% or greater. This can be viewed as a prebiotic purification step. Ribose aminooxazoline can then react with cyanoacetylene to give alpha cytidine ribonucleotide. Photoanomerization with UV light allows for inversion about the 1' anomeric centre to give the correct beta stereochemistry.
{\displaystyle {\begin{aligned}z:\ &\rho \left({\partial _{t}u_{z}}+u_{r}{\partial _{r}u_{z}}+{\frac {u_{\varphi }}{r}}{\partial _{\varphi }u_{z}}+u_{z}{\partial _{z}u_{z}}\right)\\&\quad =-{\partial _{z}p}\\&\qquad +\mu \left({\frac {1}{r}}\partial _{r}\left(r{\partial _{r}u_{z}}\right)+{\frac {1}{r^{2}}}{\partial _{\varphi }^{2}u_{z}}+{\partial _{z}^{2}u_{z}}\right)\\&\qquad +{\frac {1}{3}}\mu \partial _{z}\left({\frac {1}{r}}{\partial _{r}\left(ru_{r}\right)}+{\frac {1}{r}}{\partial _{\varphi }u_{\varphi }}+{\partial _{z}u_{z}}\right)\\&\qquad +\rho g_{z}.\end{aligned}}}
== Ecology == The Rotheca myricoides interacts with several other species. Pseumenes depressus, the Asian hornet, and Xylocopa ruficeps all visit the Rotheca myricoides. Xylocopa phalothorax, Xylocopa tranquebarorum, and Xylocopa nasalis eat the Rotheca myricoides. The plant plays a significant role in its native ecosystems by supporting pollinators like butterflie and bees. Its long corolla tubes are adapted to attract specific pollinators with long proboscises for effective pollen transfer. The plant provides food to birds that consume its drupes, helping in seed dispersal. The status on the Red List of South African plants is at "Least Concern" as assessed on 2005/06/30, as it was not highlighted as a potential taxa for conservation concern.
Sources: en.wikipedia.org
=== Intrinsic properties and resistance === Polyvinylidene fluoride expresses inherent resistance characteristics in certain high-focus applications. Namely these are: ozone oxidation reactions, nuclear radiation, UV damage, and microbiological, fungus growth. PVDF's resistance to these conditions is fairly distinctive among thermoplastic materials. PVDF's carbon and fluoride elemental stability contributes to this resistance, as well as the polymeric integration of PVDF during its processing.
In the 19th century, in Bielefeld, Germany, epileptic patients were given the prescription to spend time each day taking care of cats and dogs. The contact with the animals was found to reduce the occurrence of seizures. As early as the 1920s, people were starting to utilize the human–animal bond not just for healing, but also granting independence through service animals. In 1929, The Seeing Eye Inc. school formed to train guide dogs for the blind in the United States, inspired by dogs being trained to guide World War I veterans in Europe. Furthermore, the idea is that the human-animal bond can provide health benefits to humans as the animals "appeal to fundamental human needs for companionship, comfort, and security..." In 1980, a team of scientists at the University of Pennsylvania found that human to animal contact was found to reduce the physiological characteristics of stress; specifically, blood pressure, heart rate, respiratory rate, anxiety, and tension were all found to correlate inversely with human–pet bonding. In some cases, despite its benefits, the human–animal bond can be used for harmful purposes. The 1990s saw an increase in social and scientific awareness of the use of companion animals as a tool for domestic violence. A 1997 study found that 80% of shelters reported women staying with them had experienced their abuser threatening or harming companion animals as a form of abuse. A 2003 study by the U.S.
=== Corporate self-regulation === AI labs and companies generally abide by safety practices and norms that fall outside of formal legislation. One aim of governance researchers is to shape these norms. Examples of safety recommendations found in the literature include performing third-party auditing, offering bounties for finding failures, sharing AI incidents (an AI incident database was created for this purpose), following guidelines to determine whether to publish research or models, and improving information and cyber security in AI labs. Companies have also made commitments. Cohere, OpenAI, and AI21 proposed and agreed on "best practices for deploying language models", focusing on mitigating misuse. To avoid contributing to racing-dynamics, OpenAI has also stated in their charter that "if a value-aligned, safety-conscious project comes close to building AGI before we do, we commit to stop competing with and start assisting this project" Also, industry leaders such as CEO of DeepMind Demis Hassabis, director of Facebook AI Yann LeCun have signed open letters such as the Asilomar Principles and the Autonomous Weapons Open Letter.
Cefadroxil (formerly trademarked as Duricef) is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections. It is a bactericidal antibiotic. It was patented in 1967 and approved for medical use in 1978.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.